Recurrent Pregnancy Loss: Novel Insights and Future Directions
Abstract
Recurrent pregnancy loss (RPL), defined as the spontaneous loss of two or more pregnancies before 20 weeks of gestation, remains a complex clinical challenge with multifactorial etiology. Genetic abnormalities, uterine anomalies, endocrine disorders, antiphospholipid antibody syndrome, infections, environmental influences, and male factors contribute to its occurrence. Evaluation involves comprehensive history, endocrine and genetic testing, uterine imaging, and screening for thrombophilia and infections. Management strategies include surgical correction of uterine anomalies, pharmacological interventions (levothyroxine, metformin, cabergoline, progesterone, low-dose aspirin, LMWH), and supportive care. Emerging therapies such as preimplantation genetic testing, stem cell-derived exosome therapy, lymphocyte immunotherapy, and pharmacogenomics offer promising avenues but require further validation. Psychological support and multidisciplinary care are essential to improve outcomes. Despite advances, unexplained RPL remains prevalent, underscoring the need for precision medicine and integrative approaches to optimize reproductive success.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.